...as I said often on this thread, sooner or later our ASX blue...

...as I said often on this thread, sooner or later our ASX blue chips would either implode or face legacy threat, we saw that with Qantas, Westpac, many more, now Resmed with this Ozempic threat. Ozempic is believed to reduce sleep apnea but not conclusive.

....Resmed has lost -50% since its Aug 2021 peak.

....Buy and Hold on major blue chip companies is not as safe as we think.

5 year view then All Time
RMD Stock Price and Chart — NYSE:RMD — TradingView


UBS downgrades ResMed due to Ozempic-like competitors

Joshua Peach
Analysts at UBS have downgraded dual-listed healthtech stock ResMed, due to the rise of competitor treatments from weight loss drugs like Ozempic.
In recent months, the stock has come under increasing pressure from short-sellers, who are banking on Ozempic, the diabetes treatment which has become a popular weight loss drug, reducing demand for sleep apnoea products.
UBS analysts had flagged the rise of weight loss drugs as a potential headwind for the company earlier this year, and have subsequently slashed ResMed’s price target by 36 per cent to $US170, dropping the stock to a “Neutral” rating from a “Buy” rating
The analysts cited the likely regulatory success of Ozempic-like competitor drug SURMOUNT-OSA as a reason for the downgrade.
“The stock no longer looks exceptional on growth versus US peers,” the note said.